Help protect your baby starting with their first breath.
Pfizer’s ABRYSVO is the only maternal RSV vaccine given during weeks 32 through 36 of pregnancy to help protect newborns against severe RSV from birth through 6 months.
ABRYSVO is a CDC-recommended vaccine
The CDC recommends ABRYSVO if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). There are areas in the U.S., including southern FL, AK, HI, and the U.S. territories, where RSV does not follow typical seasonal patterns and the recommended months for maternal vaccination may differ.
Help protect infants against the risk of RSV from birth
RSV is a highly contagious respiratory virus that can make your baby sick, especially if they’re under 6 months old.
- Nearly 50% of all RSV hospitalizations during the first year occur during the first 3 months of life.
- 75-80% of hospitalizations due to RSV happened during the first 6 months of life.
Pregnant women should receive Pfizer’s ABRYSVO during weeks 32 through 36 of pregnancy.
The CDC recommends ABRYSVO if you are 32 to 36 weeks pregnant during September through January (in most of the United States). In some states, the recommended months for maternal vaccination may differ.
How does maternal immunization with ABRYSVO protect your baby?
Maternal immunization with ABRYSVO is a choice pregnant women can make to help protect their babies.
- Maternal immunization with ABRYSVO refers to the process of vaccinating a pregnant woman so protective antibodies can be passed to the baby through the placenta before birth.
- During pregnancy, your body naturally passes on antibodies that help protect your baby against bacteria and viruses in the first few months of life, before they’re old enough to develop their own protection. Pfizer’s ABRYSVO helps your body create RSV antibodies that are passed to your unborn baby to help protect them from birth through 6 months.
- Eligible pregnant women can choose to receive Pfizer’s RSV vaccine ABRYSVO between 32 and 36 weeks of pregnancy so that their baby doesn’t have to receive a shot themselves after birth.
Pfizer's vaccine ABRYSVO helps protect your baby against RSV.
ABRYSVO was studied in a clinical trial including over 7,000 pregnant women and their babies, where 3,495 pregnant women received ABRYSVO and 3,480 received a placebo. The study showed ABRYSVO reduced the risk of severe RSV by 69% compared with placebo in infants measured at 6 months after birth.
Most common side effects of Pfizer’s ABRYSVO
Pfizer’s ABRYSVO is given between weeks 32 through 36 of pregnancy
ABRYSVO was studied in clinical trials including over 7,000 pregnant women and their babies, where 3,797 pregnant women received ABRYSVO and 3,675 received a placebo.
View full prescribing information
Get to know more about RSV and protecting your baby with Pfizer’s ABRYSVO
Watch to learn more about Pfizer’s ABRYSVO
Know you’ve helped protect your baby against RSV from birth through 6 months with Pfizer’s RSV vaccine, ABRYSVO.
video
Text on screen (fine print), audio, voice over,
Text on screen: 4,928,000
Audio: [Deep breath in]
Text on screen: 4,928,001
Audio: [Deep exhale]
[humming]
Text on screen: 4,928,002
Voice Over: During your pregnancy you’ll take about 6 million breaths.
Text on screen: 4,928,003
Voice Over: Two breaths as you get…
Text on screen: PFIZER’S MATERNAL RSV VACCINE ABRYSVO
Text on screen: 5,390,542
Text on screen: 5,390,543
Text on screen: RSV is Respiratory Syncytial Virus
Text on screen: 5,390,544
Voice Over: …Pfizer’s Maternal RSV Vaccine, Abrysvo. The only maternal vaccine given between 32 through 36 weeks of pregnancy to protect babies against RSV from birth through 6 months.
Text on screen: 6,000,000 BREATHS TO MEET YOUR BABY
Voice Over: 6 million breaths to meet your baby.
Text on screen: KNOW YOU’VE HELPED PROTECT THEM AGAINST RSV.
Voice Over: Know you’ve helped protect them against RSV.
Voice Over: Abrysvo is not for everyone and may not protect all babies of vaccinated mothers. Don’t get Abrysvo if you’ve had a severe allergic reaction to its ingredients.
Text on screen: To avoid the potential risk of preterm birth with use of ABRYSVO, it should be given between weeks 32 through 36 of pregnancy.
Text on screen: [Pfizer animated logo on screen]
ABRYSVO® is a vaccine indicated for pregnant individuals at 32 through 36 weeks gestational age for the prevention of lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.
[ABRYSVO logo on screen]
Voice Over: People with a weakened immune system may have a decreased response to vaccination. The most common side effects among pregnant women are headache, pain at the injection side, muscle pain and nausea.
Text on screen: LEARN MORE ABOUT PFIZER’S MATERAL RSV VACCINE
ABRYSVO.COM
Voice Over: In clinical trials with Abrysvo, low birth weight and jaundice were reported more frequently than placebo.
Text on screen: EVERY BREATH MATTERS
Voice Over: Every breath matters.
[ABRYSVO logo]
Voice Over: Talk to your OBGYN or other healthcare provider about Pfizer’s maternal RSV vaccine, ABRYSVO.
Text on screen: Talk to your OBGYN or other healthcare provider about Pfizer’s maternal RSV vaccine, ABRYSVO
ABRYSVO.com | 1-844-989-PATH | Visit ABRYSVOPRICING.com for cost info
[Pfizer logo on screen]
Text on screen: PP-A1G-USA-0326 ©Pfizer Inc. All rights reserved. November 2023.
[Animated Pfizer Outdo Yesterday logo]
Savings and support
Talk to your doctor or pharmacist to see if Pfizer’s ABRYSVO is covered under your insurance plan. Additional savings and support options may be available at Pfizer RxPathways®
Pfizer’s ABRYSVO may be available to you at no cost in accordance with the Inflation Reduction Act.
Certain vaccines may be covered or available at lower out-of-pocket costs in Medicaid, the Children’s Health Insurance Program, Medicare Part D, or other consumer plans through the Inflation Reduction Act. For more information, visit cms.gov.
Ask About Pfizer’s ABRYSVO
Pregnancy is a time when you may have a lot of questions for your doctor. Start the conversation about RSV and Pfizer’s ABRYSVO today.
Respiratory syncytial virus (RSV) is the leading cause of hospitalization in infants. The risk of your baby being admitted to hospital with RSV is 16x higher than the flu. RSV is very easily spread to people in hospitals, at home, and in nurseries. The largest group of babies requiring hospitalization due to RSV are those aged less than 6 months old.
Other things that can put infants at risk are:
- Are born prematurely
- Are up to 12 months old, especially those 6 months and younger
- Are less than 2 years old with chronic lung disease or heart disease present from birth
- Have weakened immune systems
- Have neuromuscular disorders, including difficulty swallowing or clearing mucus from the chest
The CDC recommends ABRYSVO if you are 32 through 36 weeks pregnant during September through January (in most of the continental United States). However, there are areas in the U.S., including southern Florida, Alaska, Hawaii, and the U.S. territories, where RSV does not follow the typical seasonal patterns and the recommended months for maternal vaccination may differ.
Talk to your OB-GYN to learn more about how to protect your baby against RSV during their first RSV season and whether ABRYSVO is right for you.
Pregnant women who received ABRYSVO most commonly reported pain at the injection site, headache, muscle pain and nausea.
Jaundice, also known as temporary yellowing of the eyes and skin, was seen in 7.2% of infants in ABRYSVO group and 6.7% in the placebo group.
Low birth weight was observed in 5.1% of infants in the ABRYSVO group versus 4.4% in the placebo group.
- Am I eligible to receive ABRYSVO?
- Is it safe for my baby if I get vaccinated while pregnant?
- Is it safe for me?
- How much protection can my baby get if I receive a vaccine while pregnant?
- What vaccination options should I know about?
- When during my pregnancy should I receive a vaccine?
- If I’m uncomfortable with getting vaccinated while pregnant, what are my other options?